The 17 most recent market catalysts affecting $INSM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target
Goldman Sachs, a prominent investment bank, has reinstated its 'Buy' rating on Insmed and assigned a $188 price target. This action signals a strong vote of confidence from a major…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 55
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198
Roth Capital analyst Adam Walsh reiterated a 'Buy' rating for Insmed, signaling continued positive sentiment towards the company. However, the price target was lowered from $212 to…
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 75
Insmed To Present Five Abstracts At ERS Congress 2026, Including Late-Breaking Phase 3b ENCORE Data On ARIKAYCE In Newly Diagnosed MAC Lung Disease On September 6
This headline is a significant corporate catalyst for Insmed (INSM) due to the upcoming presentation of late-breaking Phase 3b data for ARIKAYCE in newly diagnosed MAC lung disease…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 85
Insmed Announces Japan's Ministry Of Health, Labour And Welfare Approved BRINSUPRI For Non-Cystic Fibrosis Bronchiectasis In Patients 12 Years And Older
The approval of BRINSUPRI for non-cystic fibrosis bronchiectasis in Japan is a major win for Insmed. This expands the drug's addressable market significantly beyond its previous in…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175
JP Morgan, a major investment bank, has updated its coverage on Insmed. While the 'Overweight' rating suggests a continued positive long-term view on the stock, the slight reductio…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195
Truist Securities analyst Danielle Brill reaffirmed a 'Buy' rating for Insmed and raised the price target from $185 to $195. This action signals a strengthened positive outlook fro…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Insmed and raised the price target from $161 to $169. This action signals a positive outlook from a promin…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170
Evercore ISI Group, a prominent investment bank, has maintained its 'Outperform' rating on Insmed and raised its price target from $160 to $170. This action signals continued confi…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Thursday's Pre-Market Session
The filing details pre-market trading activity for 12 healthcare stocks, with several experiencing dramatic price swings. The primary catalyst for many of these movements, both pos…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Insmed shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
This headline represents a significant corporate catalyst for Insmed. Better-than-expected financial results and an upward revision of future sales guidance directly impact investo…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate
Insmed announced a highly positive Q2 earnings report, with losses per share of $(0.06) significantly beating the $(0.73) estimate and sales of $425.486 million far exceeding the $…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est
Insmed (INSM) has announced a substantial increase in its fiscal year 2026 sales outlook, moving from a range of $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion. Thi…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
The filing reports that several Wall Street analysts have initiated coverage on five different companies, with all ratings being positive ('Outperform' or 'Buy'). This is significa…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $192
BMO Capital's initiation of coverage on Insmed with an Outperform rating and a $192 price target is a significant positive development for the company. Analyst coverage, especially…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 75
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
Insmed reported encouraging 12-month data from an open-label extension study for TPIP, its inhaled drug for pulmonary arterial hypertension (PAH). The data showed sustained improve…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Insmed Announces 12-Month TPIP OLE Data Demonstrating Sustained Improvement, Mortality Risk Reduction, And No Newly Identified Safety Signals In PAH
Insmed has released positive 12-month data from its open-label extension study for TPIP, a drug for Pulmonary Arterial Hypertension (PAH). The data shows sustained improvement in e…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $161
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Insmed and raised the price target from $160 to $161. This action signals continued bullish sentiment from…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.